Immunosuppressive agents in dermatology;Imunossupressores na dermatologia

Anais Brasileiros de Dermatologia

Volumn 85, Issue 1, 2010, Pages 9-22

  Bressan, Aline Lopes ^a   Da Silva, Roberto Souto ^a   Fontenelle, Elisa ^a,b,c,d   Gripp, Alexandre Carlos ^a  

^a HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

^b Sociedade Brasileira de Dermatologia   (Brazil)

^c Hospital Municipal Jesus   (Brazil)

^d Instituto de Dermatologia Prof Azulay   (Brazil)

Author keywords

Azathioprine; Cyclophosphamide; Cyclosporine; Immunossupressive agents; Methotrexate

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETRETIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RETINOID; TACROLIMUS;

ACNE FULMINANS; ALOPECIA AREATA; ATOPIC DERMATITIS; BLOOD TOXICITY; BULLOUS PEMPHIGOID; CANCER RISK; CARDIOTOXICITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HISTIOCYTOSIS X; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; LUPUS ERYTHEMATOSUS; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PSORIASIS; PYODERMA GANGRENOSUM; REVIEW; SCLERODERMA; SEZARY SYNDROME; SKIN CANCER; SKIN DISEASE; SYSTEMIC THERAPY; WEGENER GRANULOMATOSIS;

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; MYCOPHENOLIC ACID; SKIN DISEASES;

EID: 77952160138     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/S0365-05962010000100002     Document Type: Review

References (51)

1. Kiss MHB. Cuidado de vacinação com o paciente reumático imunossuprimido. Em: Moreira C, Castelar GR, Marques JF. Reumatologia Essencial. Guanabara Koogan; 2009. p.552-560
2. www.medonline.com.br [homepage]. Individualização da imunossupressão em pacientes transplantados renais. Manfro RC. Revista Virtual de Medicina, 2007. [Acesso em: 8 Mar 2009]. Disponível em: http://www.medonline.com.br/manfro1.html.
3. Danovitch G. Imunosuppressive medications for renal transplantation: a multiple choice question. Kidney Int. 2001;59:388-402. (Pubitemid 32055254)
4. David F, Azulay-Abulafia L, Gripp AC. Azatioprina e psoríase. An. Bras Dermatol. 1997;72:561-564
5. Nunley RJ, Wolverton S, Darst M. Systemic drugs. In: Bolognia JL, Jorizzo JL, Rapini RP. Dermatology. London: Mosby Elsevier; 2008. p.2005-2020
6. Lowitt MH, Shear NH. Pharmacogenomics and Dermatological Therapeutics. Arch Dermatol. 2001;137:1512-1514
7. Fda.gov [homepage]. Pregnancy and the drug dilemma, 2001. [acesso 8 Mar 2009]. Disponível em: http://www.fda.gov/fdac/features/2001/301-preg. html.
8. Halverstam CP, Lebwohl M. Nonstandard and off-label therapies for psoriasis. Clin Dermatol. 2008;26:546-553
9. Wise M, Callen JP. Azathioprine: a guide for the management of dermatology patients. Dermatol Ther. 2007;20:206-215 (Pubitemid 350029310)
10. Levy RA, Pacheco MS. Uso de medicamentos na gravidez e lactação. In: Moreira C, Castelar GR, Marques JF. Reumatologia essencial. Rio de Janeiro: Guanabara Koogan; 2009. p.508-517
11. Patel AP, Ewrlick RA, McCall CO. Azathioprine in dermatology: the past, the present, the future. J Am Acad Dermatol. 2006;5:390-391
12. Marques AS. Metotrexato na psoríase. In: Sociedade Brasileira de Dermatologia. Consenso brasileiro de psoríase e guias de tratamento; 2008. p.61-66
13. Kerkhof PCM, Schalkwijk J. Psoriasis. In: Bolognia JL, Jorizzo JL, Rapini RP. Dermatology. London: Mosby Elsevier; 2008. p.115-135
14. Rocha GL, Ferraro A, Argeiro AL. Tratamento da psoríase. An Bras Dermatol. 1981;56:14-18
15. Collin B, Vani A, Ogboli M, Moss C. Methotrexate treatment in 13 children with severe plaque psoriasis. Clin Exp Dermatol. 2009;34:295-298
16. Romiti R, Arnone M, Maragno L, Takahashi MDF. Psoríase na infância e na adolescência. An Bras Dermatol. 2009;84:9-22.
17. Martins GA, Arruda L. Tratamento sistêmico da psoríase - parte I: metotrexato e acitretina. An Bras Dermatol. 2004;79:263-278 (Pubitemid 38955077)
18. Ataíde DST, Esmanhoto LDK, Helmer KA, Guerra IRC, Guimarães CCG, Moritz S. Ulceração das placas psoriáticas - efeito cutâneo adverso do metotrexato em altas doses no tratamento da psoríase: relato de três casos. An Bras Dermatol. 2003;78:749-753
19. Nunes ES, Rocha GL. Psoríase e fígado. An Bras Dermatol. 1981;56:19-20.
20. Richardson SK, Gelfand JM. Update on the natural history and systemic treatment of psoriasis. Adv Dermatol. 2008;24:171-196
21. Albuquerque EMN, Klumb EM. Imunossupressores. In: Moreira C, Castelar GR, Marques JF. Reumatologia essencial. Rio de Janeiro: Guanabara Koogan; 2009. p.476-483
22. Arruda LHF, Campbell GAM, Takahashi MDF. Psoríase. An Bras Dermatol. 2001;76:141-167.
23. Fernandes EGC, Moraes AJP, Pereira RMR, Silva CAA. Artrite idiopática juvenil com fratura vertebral: relato de dois casos. Pediatria (São Paulo). 2004;26:198-202.
24. Lima HC. Fatos e mitos sobre imunomoduladores. An Bras Dermatol. 2007;82:207-221
25. Fernandes NC, Zubaty VM. Pulsoterapia com ciclofosfamida nos pênfigos: relato de sete casos. An Bras Dermatol. 2005;80:165-168
26. Perlis C, Pan TD, McDonald CJ. Cytotoxic agents. In: Comprehensive Dermatologic Drug Therapy. Wolverton SE. China: Saunders Elsevier; 2007. p.197-217.
27. Gripp AC, Lugon NV, Wrobel R, Brito MA, Assis SF, Campello AMM, et al. Pulsoterapia em buloses: relato de nove casos. An Bras Dermatol. 1992;67:309-313 (Pubitemid 23130172)
28. Taborda PRO, Taborda VBA. Granulomatose de Wegener. An Bras Dermatol. 1998;73:135-141
29. Lee SC, Koo JYM. Cyclosporine. In: Comprehensive dermatologic drug therapy. Wolverton SE. Saunders Elsevier. 2007; 11: p. 220-237
30. Yamada, Sacramento, Simis e Bohnenstengel. Ciclosporina e dermatite atópica: revisão bibilográfica: 1993-1998. An Bras Dermatol. 2001;76:617-624
31. Griffiths CEM, Madan V. Systemic cyclosporine and tacrolimus in dermatology. Dermatologic Therapic. 2007;20:239-250
32. Rivitti EA. Alopecia areata: revisão e atualização. An Bras Dermatol. 2005;80:57-68.
33. Zanini M, Lacaz EG, Neves SRC, Paschoal LHC. Emprego clínico da ciclosporina em Dermatologia. An Bras Dermatol. 2001;76:361-378
34. Souza CS, Chiossi MPV, Takada MH, Foss NT, Roselino AMF. Pioderma gangrenoso: casuística e revisão de aspectos clínico- laboratoriais e terapêuticos. An Bras Dermatol. 1999;74:465-472
35. Griffiths CEM, Dubertret L, Ellis CN, Finlay AY, Finzi AF, Ho VC, et al. Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol. 2004;150:11-23. (Pubitemid 38903574)
36. Griffiths CEM, Katsambas A, Dijkmans BA, Finlay AY, Ho VC, Johnston A, et al. Update on the use of cyclosporine in immune-mediated dematoses. Br J Dermatol. 2006;155:1-16. (Pubitemid 43855773)
37. Schwartz J, Magnabosco EM, Oliveira MTC, Abreu MLM, Biasi TB. Ciclosporina microemulsão no tratamento da psoríase grave: estudo de nove casos. An Bras Dermatol. 2002;77:79-86. (Pubitemid 34289942)
38. Ho VC. The use of ciclosporin in psoriasis: a clinical review. Br J Dermatol. 2004;150 Suppl 67:1-10.
39. Ferreira DM, Brandão MG, Nascimento MCF, Carneiro SCS, Pereira AC. Ciclosporina A em psoríase. An Bras Dermatol. 1991;66:203-205
40. Takahashi MDF. Ciclosporina A na psoríase grave. An Bras Dermatol. 1993;68:173-180.
41. Correia SS, Boraso RZ, Silva Jr HT, Almeida FA. Ciclosporina no tratamento do pênfigo vulgar. An Bras Dermatol. 1993;68:291-293
42. Warren RB, Griffiths CEM. Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. Clin Dermatol. 2008;26:438-447
43. Heller M, Shuin HT, Orlow SJ, Schaffer JV. Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients. Br J Dermatol. 2007;157:127-132
44. Orvis AK, Wesson ST, Breza TS, Church AA, Mitchell CL, Watkins SW. Mycophenolate mofetil in dermatology. J Am Acad Dermatol. 2009;60:183-199
45. Esmaili N, Chams-Davatchi C, Valikhani M, Farshidfar F, Parvaneh N, Tamizifar B. Treatment of pemphigus vulgaris with mycofenolate mofetil as a steroid-sparing agent. Eur J Dermatol. 2008;18:159-164
46. Beiisert S, Werfel T, Frieling U, Böhm M, Sticherling M, Stadler R, et al. A comparision of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol. 2006;142:1447-1454
47. Beiisert S, Werfel T, Frieling U, Böhm M, Sticherling M, Stadler R, et al. A comparision of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol. 2007;143:1536-1542
48. Kawashita MY, Tasi K, Aoki V, Santi CG, Maruta CW, Rivitti E. Mycophenolate mofetil as an adjuvant therapy for classic and endemic pemphigus foliaceus. J Dermatol. 2005;32:574-580 (Pubitemid 41206440)
49. Cunha PR, Barraviera SRCS. Dermatoses bolhosas auto-imunes. An Bras Dermatol. 2009;84:111-124
50. Costa IMC, Nogueira LSC. Pioderma gangrenoso e artrite reumatóide: relato de caso. An Bras Dermatol. 2005;80:81-82 (Pubitemid 40462687)
51. Shapiro LE, Knowles SR, Shear NH. Drug interactions. In: Bolognia JL, Jorizzo JL, Rapini RP. Dermatology. London: Mosby Elsevier; 2008. p.2021-2033